Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

BRISTOL-MYERS Aktie

 >BRISTOL-MYERS Aktienkurs 
40.31 EUR    -2.8%    (Tradegate)
Ask: 40.23 EUR / 248 Stück
Bid: 39.945 EUR / 250 Stück
Tagesumsatz: 7399 Stück
Realtime Kurs von 8 bis 22 Uhr!
Aktie über LYNX handeln
>BRISTOL-MYERS Performance
1 Woche: +1,1%
1 Monat: -7,4%
3 Monate: -9,6%
6 Monate: -26,0%
1 Jahr: +7,4%
laufendes Jahr: -26,8%
>BRISTOL-MYERS Aktie
Name:  BRISTOL-MYERS SQUIBBDL-10
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US1101221083 / 850501
Symbol/ Ticker:  BRM (Frankfurt) / BMY (NYSE)
Kürzel:  FRA:BRM, ETR:BRM, BRM:GR, NYSE:BMY
Index:  S&P500
Webseite:  https://www.bms.com/
Marktkapitalisierung:  87290 Mio. EUR
Umsatz:  41129.6 Mio. EUR
EBITDA:  16550.26 Mio. EUR
Gewinn je Aktie:  1.994 EUR
Schulden:  44263.53 Mio. EUR
Liquide Mittel:  10170.16 Mio. EUR
Umsatz-/ Gewinnwachstum:  -5.6% / -
KGV/ KGV lG:  18.61 / 7.41
KUV/ KBV/ PEG:  2.13 / 5.84 / 2.26
Gewinnm./ Eigenkapitalr.:  11.38% / 31.99%
Dividende je Aktie:  2.264 EUR
Dividendenrendite/ -schätzung:  5.3% / 5.09%
Div. Historie:  04.04.25 - 0.56103€
03.01.25 - 0.60388€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  BRISTOL-MYERS, BRISTOL MYERS
Letzte Datenerhebung:  13.07.25
>Eigentümer
Aktien: 2040 Mio. St.
f.h. Aktien: 2030 Mio. St.
Insider Eigner: 0.07%
Instit. Eigner: 82.21%
 >Anleihen 
Es sind 1 Anleihen zur BRISTOL-MYERS Aktie bekannt.
>Peer Group

 
11.07.25 - 17:30
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now? (Zacks)
 
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds....
10.07.25 - 01:02
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
 
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $47.66, denoting a +1.32% move from the preceding trading day....
09.07.25 - 08:45
BioNTech-Aktie weiter auf Kurs nach Milliardendeal mit Bristol Myers Squibb (Finanzen.net)
 
BioNTech hat jüngst einen spektakulären Milliarden-Deal mit Bristol Myers Squibb geschlossen. Diese Impulse treiben die Aktie außerdem an....
04.07.25 - 08:48
BioNTech-Aktie vor Durchbruch? Milliarden-Deal mit Bristol Myers Squibb katapultiert Krebstherapie in neue Dimension (Finanzen.net)
 
BioNTech sichert sich einen bahnbrechenden 3,5-Milliarden-Dollar-Deal mit Bristol Myers Squibb zur Entwicklung und Vermarktung des vielversprechenden Krebsantikörpers BNT327....
03.07.25 - 16:45
Will The Decline in Legacy Drugs Pull Down BMY′s Top Line? (Zacks)
 
Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio....
02.07.25 - 23:45
XETR: DIVIDEND/INTEREST INFORMATION - 03.07.2025 - BRM (XETRA)
 
Das Instrument BRM US1101221083 BRISTOL-MYERS SQUIBBDL-10 EQUITY wird ex Dividende/Zinsen gehandelt am 03.07.2025 The instrument BRM US1101221083 BRISTOL-MYERS SQUIBBDL-10 EQUITY has its ex-dividend/interest day on 03.07.2025...
02.07.25 - 16:48
IDEXX, DexCom lead S&P 500 healthcare gains in Q2; UnitedHealth and Bristol Myers Squibb among top laggards (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
02.07.25 - 01:01
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note (Zacks)
 
Bristol Myers Squibb (BMY) closed at $47.51 in the latest trading session, marking a +2.64% move from the prior day....
01.07.25 - 23:45
XETR: DIVIDEND/INTEREST INFORMATION - 03.07.2025 - BRM (XETRA)
 
Das Instrument BRM US1101221083 BRISTOL-MYERS SQUIBBDL-10 EQUITY wird cum Dividende/Zinsen gehandelt am 02.07.2025 und ex Dividende/Zinsen am 03.07.2025 The instrument BRM US1101221083 BRISTOL-MYERS SQUIBBDL-10 EQUITY has its pre-dividend/interest day on 02.07.2025 and its ex-dividend/interest day on 03.07.2025...
01.07.25 - 19:12
Our bottom 5 stocks for the first half of 2025 — and why we still own them (CNBC)
 
This is what it will take to for a turnaround in shares of Salesforce, Apple, Bristol Myers, DuPont and Danaher....
01.07.25 - 14:03
Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer (Business Wire)
 
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced the appointment of Shishir Gadam, Ph.D., as chief technical officer. Dr. Gadam has extensive experience in the biotechnology industry and brings deep expertise and leadership in biologics development and manufacturing to Marea Therapeutics. Dr. Gadam was most recently chief technical officer at Cargo Therapeutics and responsible for technical operations for the cell therapy portfolio. Prior to Cargo, he held the position of vice president and head of cell therapy global manufacturing sciences & technology at Juno therapeutics, a Celgene company and Bristol Myers Squibb where he was instrumental in launch of two cell therapy commercial CAR-T products. During his tenure at Genetech/Roche from 2006-2018, he held positions of increasing responsibility acr...
30.06.25 - 22:45
Are Options Traders Betting on a Big Move in Bristol-Myers Squibb Stock? (Zacks)
 
Investors need to pay close attention to BMY stock based on the movements in the options market lately....
27.06.25 - 15:09
Bristol Myers wins favorable FDA label updates for cell therapies Breyanzi and Abecma (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.06.25 - 19:00
This Once Dominant Dividend Stock May Be About to Come Back to Life in July (24/7 Wall St.)
 
For income investors seeking a timely value stock to buy on the dip, former dividend darling Bristol-Myers Squibb (NYSE:BMY) may fit the bill as one of the top names to watch in the month of July. Undoubtedly, the stock has been under harsh pressure since peaking in the back half of 2022, now down more […] The post This Once Dominant Dividend Stock May Be About to Come Back to Life in July appeared first on 24/7 Wall St.....
25.06.25 - 06:24
US-Klage gegen Pharmafirma Britol-Myers wegen Krebsmittel (Cash)
 
Pharma - Wegen angeblich wettbewerbswidrigen Verhaltens zerrt die US-Krankenkasse Cigna den Pharmakonzern Bristol-Myers Squibb vor Gericht....
24.06.25 - 20:42
Cigna sues Bristol Myers for alleged monopoly over blockbuster cancer drug (CNBC)
 
Cigna accused Bristol Myers Squibb of violating antitrust law by keeping generic versions of its blood cancer drug Pomalyst off the market to retain a monopoly....
24.06.25 - 20:03
Cigna files antitrust case against Bristol Myers over Pomalyst sales (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
20.06.25 - 17:30
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now? (Zacks)
 
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown....
18.06.25 - 00:01
Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies (Caixin)
 
A wave of multibillion-dollar deals is reshaping the pharmaceutical industry, as global giants such as Pfizer Inc. and Bristol Myers Squibb Co. turn to China's rising biotech sector in search of the next generation of blockbuster drugs. ... Read more...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Man mag Amphion sein und Fels und Wald bewegen, deswegen kann man doch nicht Bauern widerlegen. - Christian Fürchtegott Gellert
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!